Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alcohol Use
Viboliv to enter the hepatoprotectives market
November 18th, 2005
Viboliv (Metadoxine) has been launched nationwide by Dr. Reddy's in both 500 mg tablet and 300 mg injectable form. Metadoxine has a direct effect on alcohol metabolism, accelerating the transformation of alcohol into acetaldehyde and thereon its urinary excretion. It aids in preventing liver damage resulting from prolonged alcohol intake and helps in reversing fatty liver degeneration, according to the company. It is indicated for fatty liver, acute, and chronic alcohol intoxication. Viboliv is in licensed from Eurodrug Laboratories Belgium, and is the third licensed product to be introduced in the calendar year 2005. ...
Source: Drug Week (2005-11-18)
|
